scholarly journals Hyperlipidemic Rabbit Models for Anti-Atherosclerotic Drug Development

2020 ◽  
Vol 10 (23) ◽  
pp. 8681
Author(s):  
Manabu Niimi ◽  
Yajie Chen ◽  
Haizhao Yan ◽  
Yao Wang ◽  
Tomonari Koike ◽  
...  
Keyword(s):  
Risk Factor ◽  
Drug Development ◽  
Apolipoprotein B ◽  
Molecular Mechanisms ◽  
Lipoprotein Metabolism ◽  
Mrna Editing ◽  
Experimental Animals ◽  
Transfer Protein ◽  
Hyperlipidemic Rabbit ◽  
Plasma Apolipoprotein

Hyperlipidemia or dyslipidemia is a major risk factor for atherosclerotic diseases. Experimental animals play an important role in elucidating the molecular mechanisms of the pathophysiology of hyperlipidemia as well as in drug development. Rabbits are one of the most suitable models to study human hyperlipidemia because many features of the lipoprotein metabolism of rabbits are similar to those of humans such as LDL-rich lipoproteins in plasma, apolipoprotein B mRNA editing, and cholesteryl ester transfer protein. Currently, three types of rabbit models are commonly used for studying hyperlipidemia: (1) diet-induced hyperlipidemic rabbits, (2) spontaneous hyperlipidemic rabbits, and (3) gene-manipulated rabbits (transgenic and knockout rabbits). In this review, we give an overview of the features of hyperlipidemic rabbits and discuss the usefulness of rabbits for the development of anti-atherogenic drugs.

Molecular mechanisms of apolipoprotein B mRNA editing

2001 ◽  
Vol 12 (2) ◽  
pp. 159-165 ◽  
Author(s):  
Shrikant Anant ◽  
Nicholas O. Davidson
Keyword(s):  
Apolipoprotein B ◽  
Molecular Mechanisms ◽  
Mrna Editing

Increased hepatic synthesis and accumulation of plasma apolipoprotein B100 in copper-deficient rats does not result from modification in apolipoprotein B mRNA editing

Lipids ◽  
1996 ◽  
Vol 31 (4) ◽  
pp. 433-436 ◽  
Author(s):  
Fatiha Nassir ◽  
Federico Giannoni ◽  
Andrzej Mazur ◽  
Yves Rayssiguier ◽  
Nicholas O. Davidson
Keyword(s):  
Apolipoprotein B ◽  
Mrna Editing ◽  
Apolipoprotein B100 ◽  
Hepatic Synthesis ◽  
Plasma Apolipoprotein

scholarly journals Mutational analysis of apolipoprotein B mRNA editing enzyme (APOBEC1): structure–function relationships of RNA editing and dimerization

1999 ◽  
Vol 40 (4) ◽  
pp. 623-635 ◽  
Author(s):  
Ba-Bie Teng ◽  
Scott Ochsner ◽  
Qian Zhang ◽  
Kizhake V. Soman ◽  
Paul P. Lau ◽  
...  
Keyword(s):  
Structure Function ◽  
Rna Editing ◽  
Apolipoprotein B ◽  
Mutational Analysis ◽  
Mrna Editing ◽  
Editing Enzyme

scholarly journals Apolipoprotein B mRNA editing. Direct determination of the edited base and occurrence in non-apolipoprotein B-producing cell lines.

1990 ◽  
Vol 265 (36) ◽  
pp. 22446-22452 ◽  
Author(s):  
K Boström ◽  
Z Garcia ◽  
K S Poksay ◽  
D F Johnson ◽  
A J Lusis ◽  
...  
Keyword(s):  
Cell Lines ◽  
Apolipoprotein B ◽  
Direct Determination ◽  
Mrna Editing

scholarly journals Influence of Peripheral Artery Disease and Statin Therapy on Apolipoprotein Profiles

2013 ◽  
Vol 2013 ◽  
pp. 1-7
Author(s):  
Andrew W. Gardner ◽  
Petar Alaupovic ◽  
Donald E. Parker ◽  
Polly S. Montgomery ◽  
Omar L. Esponda ◽  
...  
Keyword(s):  
Physical Activity ◽  
Myocardial Infarction ◽  
Statin Therapy ◽  
Peripheral Artery Disease ◽  
Apolipoprotein B ◽  
Ldl Cholesterol ◽  
Risk Profile ◽  
Peripheral Artery ◽  
Artery Disease ◽  
Plasma Apolipoprotein

Apolipoprotein B is a stronger predictor of myocardial infarction than LDL cholesterol, and it is inversely related to physical activity and modifiable with exercise training. As such, apolipoprotein measures may be of particular relevance for subjects with PAD and claudication. We compared plasma apolipoprotein profiles in 29 subjects with peripheral artery disease (PAD) and intermittent claudication and in 39 control subjects. Furthermore, we compared the plasma apolipoprotein profiles of subjects with PAD either treated (n=17) or untreated (n=12) with statin medications. For the apolipoprotein subparticle analyses, subjects with PAD had higher age-adjusted Lp-B:C (P<0.05) and lower values of Lp-A-I:A-II (P<0.05) than controls. The PAD group taking statins had lower age-adjusted values for apoB (P<0.05), Lp-A-II:B:C:D:E (P<0.05), Lp-B:E + Lp-B:C:E (P<0.05), Lp-B:C (P<0.05), and Lp-A-I (P<0.05) than the untreated PAD group. Subjects with PAD have impaired apolipoprotein profiles than controls, characterized by Lp-B:C and Lp-A-I:A-II. Furthermore, subjects with PAD on statin medications have a more favorable risk profile, particularly noted in multiple apolipoprotein subparticles. The efficacy of statin therapy to improve cardiovascular risk appears more evident in the apolipoprotein sub-particle profile than in the more traditional lipid profile of subjects with PAD and claudication. This trial is registered with ClinicalTrials.govNCT00618670.

Sign in / Sign up

Export Citation Format

Share Document